Evaluation of Dosimetric Parameters for Tumor Therapy with $^{177}$Lu and $^{90}$Y Radionuclides in Gate Monte Carlo Code

Milad Peer-Firozjaei¹, Mohammad Ali Tajik-Mansoury²*, Raheb Ghorbani³,⁴, Mahdi Mazinani¹

ABSTRACT

Background: $^{90}$Y and $^{177}$Lu are two well-known radionuclides used in radionuclide therapy to treat neuroendocrine tumors.

Objective: This current study aims to evaluate, compare and optimize tumor therapy with $^{90}$Y and $^{177}$Lu for different volumes of the tumor using the criterion of self-absorbed dose, cross-absorbed dose, absorbed dose profile, absorbed dose uniformity, and dose-volume histogram (DVH) curve using Gate Monte Carlo simulation code.

Material and Methods: In our analytical study, Gate Monte Carlo simulation code has been used to model tumors and simulate particle transport. Spherical tumors were modeled from radius 0.5 to 20 mm. Tumors were uniformly designed from water (soft tissue reagent). The full energy spectrum of each radionuclide of $^{177}$Lu and $^{90}$Y was used in the total volume of tumors with isotropic radiation, homogeneously. Self-absorbed dose, cross-absorbed dose, absorbed dose profile, absorbed dose uniformity, and DVH curve parameters were evaluated.

Results: The absorbed dose for $^{90}$Y is higher than $^{177}$Lu in all tumors (p-value <5%). The uniformity of the absorbed dose for $^{177}$Lu is much greater than $^{90}$Y. As the tumor size increases, the DVH graph improves for $^{90}$Y.

Conclusion: Based on self-absorbed dose, cross-absorbed dose, absorbed dose uniformity, and DVH diagram, $^{177}$Lu and $^{90}$Y are appropriate for smaller and larger tumors, respectively. Next, we can evaluate the appropriate cocktail of these radionuclides, in terms of the type of composition, for the treatment of tumors with a specific size.

Keywords
Radionuclide Tumor Therapy; Gate Monte Carlo; Dosimetry; DVH; Lutetium-177; Yttrium-90

Introduction

Radionuclide radiation therapy is an important method for treating the disseminated tumors and metastases [1]. A major advantage of radionuclide therapy is that it treats not only primary large tumors and macro-metastases but also small tumors and micro-metastases [1, 2].

As tumor tissue absorbs radiopharmaceuticals, healthy tissue also absorbs them and irradiated, and radionuclide therapy planning thus aims is to deliver the highest absorbed dose to the tumor tissue and the least absorbed dose to the healthy tissue.

*Corresponding author: Mohammad Ali Tajik-Mansoury
Department of Medical Physics, Semnan University of Medical Science, Semnan, Iran
E-mail: m_tajik@semums.ac.ir

Received: 3 January 2021
Accepted: 5 April 2021
damage to the organ at risk [3-5].

\(^{90}\)Y and \(^{177}\)Lu are two well-known radionuclides used in radionuclide therapy of neuro-endocrine tumors. Based on the previous literature, \(^{177}\)Lu and \(^{90}\)Y have low and high energy beta particles, respectively, and also they are widely used for treating smaller and larger tumors [6-9].

In the clinical situation, the most serious part of treatment planning of radionuclide therapy is determining the measure of prescribed radioactive material for improving treatment, based on the maximum absorbed dose to the tumor tissues and the minimum absorbed dose to critical organs. Also, there are some limitations, including methods for estimating dose distribution in tumors and tissues around tumors. As a result, proper treatment planning is an accurate and fast method of dose estimation to optimize treatment planning. If the dosimetry technique adopted is not appropriate, we may experience an increase in the absorbed dose of around the tumor and an insufficient absorbed dose inside the tumor as a result of estimating the wrong dose, leading to cancer reversion and low utilization [4, 8, 10].

Evaluation of self-dose and cross-dose of tumors in radionuclide therapy is important to examine the treatment planning [9].

It is also important to study the tumor’s absorbed dose profile to evaluate the tumor absorbed dose’s flatness, which directly affects the optimal treatment [11].

Dose Volume Histogram (DVH) and external radiotherapy can be utilized to examine the treatment planning of radionuclide therapy [12].

It seems that the study of physical parameters can well evaluate treatment planning in radionuclide therapy. Therefore, the current study aims to evaluate, compare and optimize tumor therapy with \(^{90}\)Y and \(^{177}\)Lu for different sizes of tumors using the criteria of self-absorbed dose, cross-absorbed dose, absorbed dose profile, dose uniformity, and DVH curve, using Gate Monte Carlo simulation code.

Material and Methods

In this analytical study, Gate version 8.1 (based Geant4 package version 10.4) Monte Carlo simulation code has been used to model tumors and simulate particle transport. Spherical tumors were modeled from radius 0.5 to 20 mm (volume of 0.4 to 4000 mm\(^3\)) [13]. The dimension of an area outside the tumor is greater than three times the maximum range of each radionuclide for calculating the cross dose. Tumors were uniformly designed from water (soft tissue reagent). The total energy spectrum of \(^{177}\)Lu and \(^{90}\)Y radionuclides were used in the total volume of tumors with isotropic radiation, homogeneously [14]. The characteristics of these radionuclides are shown in Table 1. To achieve more accuracy, “standard physical processes” were used to perform the simulation, which included Photoelectric, Compton, Rayleigh Scattering, Gamma Conversion, Electron Ionization, Bremsstrahlung, and Multiple Scattering processes [9]. The output files from the simulation include the dose and dose uncertainty files. The absorbed dose, \(D_m\), is calculated by energy deposited by equation 1.

\[
D_m = \frac{\text{Energy deposited}}{\text{Volume}}
\]

\(D_m\) finally divided by the number of primary particles, and then the absorbed dose is eventually reported in Gy/Bq.s. The absorbed dose uniformity (flatness) inside the tumor (given from dose profile) is defined based on equation 2 [11, 15]:

\[
%\text{flatness} = \frac{D_{\text{max}} - D_{\text{min}}}{D_{\text{max}} + D_{\text{min}}} \times 100
\]

We also plot the relative Dose Volume Histogram (DVH) for all tumors and radionuclides.

### Table 1: Characteristic parameters of \(^{177}\)Lu and \(^{90}\)Y.

| Isotope       | \(T_{1/2}\) (day) | Average energy (Kev) | Maximum range (mm) |
|---------------|-------------------|----------------------|-------------------|
| Yttrium\(^{90}\) | 2.67              | 935.3                | 11                |
| Lutetium\(^{177}\) | 6.7               | 133.5                | 2.2               |
To achieve statistical uncertainty less than 5%, the number of primary particles for simulation was considered $10^9$ and $10^8$ for $^{177}$Lu and $^{90}$Y, respectively.

Results

Absorbed dose

The calculated self-absorbed dose for $^{177}$Lu and $^{90}$Y radionuclides are presented for all tumors in Table 2. The cross absorbed dose is also shown in Table 3.

Using the Mann-Whitney test, we analyzed the absorbed doses for $^{177}$Lu and $^{90}$Y radionuclides in all tumor sizes and concluded a substantial difference between absorbed doses for $^{177}$Lu and $^{90}$Y in all tumor sizes.

The absorbed dose for $^{90}$Y is greater than $^{177}$Lu (p-value <5%) in all tumor sizes.

The self-absorbed dose according to the tumor’s dimension is presented in Figure 1, which is qualitatively observed that as the

### Table 2: Self-absorbed doses (Gy/Bq.s) for $^{177}$Lu and $^{90}$Y in different sizes of tumors.

| Radionuclide radius of tumors (mm) | $^{90}$Y     | $^{177}$Lu  |
|-----------------------------------|--------------|-------------|
| 0.5                               | 1.43E-08     | 1.349E-09   |
| 1                                 | 1.96E-09     | 1.84E-10    |
| 2                                 | 2.25E-10     | 2.41E-11    |
| 3                                 | 7.75E-11     | 7.27E-12    |
| 4                                 | 3.0E-11      | 3.10E-12    |
| 5                                 | 1.70E-11     | 1.50E-12    |
| 6                                 | 1.05E-11     | 9.27E-13    |
| 8                                 | 4.73E-12     | 3.94E-13    |
| 10                                | 2.71E-12     | 2.03E-13    |
| 11                                | 1.53E-12     | 3.06E-13    |
| 12                                | 1.18E-12     | 1.18E-13    |
| 15                                | 6.08E-13     | 6.08E-14    |
| 18                                | 9.45E-13     | 3.54E-14    |
| 20                                | 5.19E-13     | 2.59E-14    |

### Table 3: (Cross-dose/total dose)×100 for $^{177}$Lu and $^{90}$Y different sizes of tumors.

| Radionuclide radius of tumors (mm) | $^{90}$Y     | $^{177}$Lu  |
|-----------------------------------|--------------|-------------|
| 0.5                               | 0.0026       | 0.00062     |
| 1                                 | 0.0193       | 0.0044      |
| 2                                 | 0.139        | 0.028       |
| 3                                 | 0.369        | 0.085       |
| 4                                 | 0.786        | 0.184       |
| 5                                 | 1.387        | 0.328       |
| 6                                 | 2.044        | 0.518       |
| 8                                 | 3.778        | 1.038       |
| 10                                | 5.541        | 1.726       |
| 11                                | 6.289        | 1.072       |
| 12                                | 7.515        | 2.552       |
| 15                                | 10.475       | 3.995       |
| 18                                | 7.008        | 5.612       |
| 20                                | 10.256       | 6.748       |

### Figure 1: Absorbed dose for $^{177}$Lu and $^{90}$Y in different sizes of the tumors.
tumor size increases the difference of $^{177}$Lu and $^{90}$Y decreases. Figure 2 shows the ratio of cross absorbed dose to total-absorbed dose as a function of tumor size. By increasing tumor size, the delivered absorbed dose to the outside of the tumor increases for $^{177}$Lu and $^{90}$Y, but from one size onwards, this reduction is gradual, and the extra-tumor doses for $^{177}$Lu and $^{90}$Y are almost constant.

**Flatness**

Absorbed dose profiles of $^{177}$Lu and $^{90}$Y for a special tumor are shown in Figure 3 as an example. The absorbed dose flatness, which is a function of tumor size, is presented in Table 4. As seen, the flatness of $^{177}$Lu is better than $^{90}$Y. In addition, Figures 4 and 5 show the flatness values according to distance.

Table 5 shows Pearson coefficient values (showing the graph’s slope) with the significant level for determining the amount of uniformity improvement with increasing tumor size. It is observed that as tumor size increases, the uniformity of the absorbed dose of $^{177}$Lu and $^{90}$Y improves. It is worth noting that the rate of $^{90}$Y absorbed dose uniformity improves greater than that of $^{177}$Lu (p-value= 0.05).

**Dose Volume Histogram (DVH)**

The relative volume as a function of relative dose diagrams for $^{177}$Lu and $^{90}$Y radionuclides and tumor with the sizes of 1, 10 and, 20 mm, as representatives of all tumor sizes, are shown in Figure 6. It is understandable that as the tumor size increases, the DVH graph improves for $^{90}$Y as well. In smaller tumors, for $^{90}$Y, energy is transferred to a smaller volume of tumor space than in larger ones.

---

**Figure 2:** Graph of (Cross-dose/total-dose)*100 for different sizes of tumors.

**Figure 3:** Dose profile of $^{90}$Y and $^{177}$Lu for 0.5 mm radius of tumor.
Discussion

For all tumors, the absorbed dose for $^{90}$Y is more than $^{177}$Lu, which because of the higher energy of beta particles in $^{90}$Y compared to $^{177}$Lu. This issue is in accordance with previous work such as Enger et al. [9] in 2008 and O. ‘Donoghue et al. [13] in 1995.

Given that the absorbed dose profile was studied in the past, it seems that this parameter and the absorbed dose uniformity of the tumor can help to improve the treatment planning of radionuclide therapy.

Our study examined the absorbed dose uniformity and concluded that the flatness of $^{177}$Lu is better than $^{90}$Y, i.e. the absorbed dose variation for $^{177}$Lu is less than $^{90}$Y, and $^{177}$Lu delivers a more uniform absorbed dose to the entire tumor volume and ultimately improves tumor treatment.

Table 4: Dose flatness inside the tumors for $^{177}$Lu and $^{90}$Y.

| Radionuclide radius of tumors (mm) | $^{90}$Y | $^{177}$Lu |
|-----------------------------------|--------|-----------|
| 0.5                               | 17.88  | 9.18      |
| 1                                 | 18.38  | 6.82      |
| 2                                 | 16.57  | 10.21     |
| 3                                 | 14.72  | 12.57     |
| 4                                 | 17.67  | 10.56     |
| 5                                 | 13.98  | 11.20     |
| 6                                 | 11.85  | 11.89     |
| 8                                 | 11.75  | 15.11     |
| 10                                | 9.68   | 14.52     |
| 11                                | 8.09   | 9.27      |
| 12                                | 7.06   | 9.21      |
| 15                                | 4.84   | 6.22      |
| 18                                | 7.80   | 6.96      |
| 20                                | 7.46   | 7.12      |

Figure 4: Dose flatness for $^{177}$Lu as a function of tumor radius.

Figure 5: Dose flatness for $^{90}$Y as a function of tumor radius.
Table 5: Pearson coefficient values and significant levels for correlation of absorbed dose uniformity with tumor radius for $^{177}$Lu and $^{90}$Y.

| Radionuclide | Pearson coefficient | sig  |
|--------------|---------------------|------|
| $^{177}$Lu   | -0.599              | 0.014|
| $^{90}$Y     | -0.820              | 0.000|

Figures 4 and 5 show the absorbed dose uniformity values inside the tumors for $^{177}$Lu and $^{90}$Y. Also, for determining the amount of uniformity improvement with increasing tumor size, Pearson coefficient values (showing the graph’s slope) with a significant value are shown in Table 5. It is observed that with increasing tumor size, the absorbed dose uniformity of $^{177}$Lu and $^{90}$Y radionuclides improves, and it is noteworthy that the rate of $^{90}$Y absorbed dose uniformity improves greater than that of $^{177}$Lu. DVH can also be used to examine treatment planning in radionuclide therapy [12].

In our study, we also have drawn DVH curves for $^{177}$Lu and $^{90}$Y in all tumors. By evaluating the DVH curves, it can be realized that $^{177}$Lu is more suitable than $^{90}$Y for smaller tumors because $^{177}$Lu transfers the energy of the beta particles to the larger space of the small tumors.

$^{90}$Y transfers a higher dose to the tumor, while covers less volume of the tumor. Moreover, it seems that with increasing tumor size, the DVH curve improves for $^{90}$Y. Thus, $^{90}$Y can be used to treat larger tumors; however, it should be mentioned that using $^{90}$Y causes a non-uniform dose within the tumor and increases the dose to surrounding organs.

According to the obtained results, $^{177}$Lu has better dose uniformity and DVH than $^{90}$Y for smaller tumors, and also delivers lower absorbed dose to outside area of the tumors. The disadvantages of $^{177}$Lu are unfavorable DVH for larger tumors and delivers low absorbed dose in all tumors. The benefits of $^{90}$Y are more tumor dose, and more favorable DVH for larger tumors, and its disadvantage is less absorbed dose uniformity and a more dose outside of the tumor.

In terms of the impact of tumor size on physical parameters in tumor therapy, we can conclude that by increasing tumor size: 1- the absorbed dose difference between $^{177}$Lu and $^{90}$Y decreases, 2- the absorbed dose flatness improves, and 3- the DVH diagram for $^{177}$Lu and $^{90}$Y worsens and improves, respectively.

By examining the parameters of self-absorbed dose, cross-absorbed dose, absorbed dose uniformity, and DVH diagram, the results of our work support the strategy of using

![Figure 6](image-url)
Radionuclide Therapy with Monte Carlo

177\textsuperscript{Lu} and 90\textsuperscript{Y} for treatment of small and large tumors, respectively, in order to use the advantages of each radionuclide for better tumor treatment [4, 5, 16, 17].

**Conclusion**

In targeted radionuclide therapy, the physical parameters of self-absorbed dose, cross-absorbed dose, absorbed dose uniformity, and DVH diagram could be utilized to evaluate the treatment planning system. By examining these parameters, it can be concluded that 177\textsuperscript{Lu} and 90\textsuperscript{Y} are appropriate for smaller and larger tumors, respectively. In addition, we can evaluate the appropriate cocktail of these radionuclides, in terms of the type of composition, for the treatment of tumors with a specific size.

**Conflict of Interest**

None

**References**

1. Brans B, Linden O, Giammarile F, Tennvall J, Punt C. Clinical applications of newer radionuclide therapies. *European Journal of Cancer*. 2006;42(8):994-1003. doi: 10.1016/j.ejca.2005.12.020. PubMed PMID: 16564689.

2. Saha GB. Physics and radiobiology of nuclear medicine. Springer Science & Business Media; 2012. doi: 10.1007/978-0-387-36281-6.

3. Stigbrand T, Carlsson J, Adams GP, editors. Targeted radionuclide tumor therapy: Biological aspects. New York: Springer; 2008. doi: 10.1007/978-1-4020-8696-0.

4. Zavgorodni SF. A model for dose estimation in therapy of liver with intraarterial microspheres. *Phys Med Biol*. 1996;41(11):2463-80. doi: 10.1088/0031-9155/41/11/016. PubMed PMID: 8938039.

5. Zweit J. Radionuclides and carrier molecules for therapy. *Phys Med Biol*. 1996;41(10):1905-14. doi: 10.1088/0031-9155/41/10/004. PubMed PMID: 8912370.

6. Ljungberg M, Celler A, Konijnenberg MW, EckermanKF, Dewaraja YK, Sjögreen-Gleisner K. MIRD pamphlet no. 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. *J Nucl Med*. 2016;57(1):151-62. doi: 10.2967/jnumed.115.159012. PubMed PMID: 26471692.

7. Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikolajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90 Y-DOTATATE and tandem 90 Y/177 Lu-DOTATATE: which is a better therapy option? *Eur J Nucl Med Mol Imaging*. 2011;38(10):1788-97. doi: 10.1007/s00259-011-1833-x. PubMed PMID: 21553086. PubMed PMCID: PMC3168754.

8. Huizing DMV, Verheij M, Stokkel MPM. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review. *EJNMMI Res*. 2018;8(1):1-11. doi: 10.1186/s13550-018-0443-z. PubMed PMID: 30159614. PubMed PMCID: PMC6115319.

9. Enger SA, Hartman T, Carlsson J, Lundqvist H. Cross-fire doses from \(\beta\)-emitting radionuclides in targeted radiotherapy. A theoretical study based on experimentally measured tumor characteristics. *Phys Med Biol*. 2008;53(7):1909-20. doi: 10.1088/0031-9155/53/7/007. PubMed PMID: 18364546.

10. Erdi AK, Erdi YE, Yorke ED, Wessels BW. Treatment planning for radio-immunotherapy. *Phys Med Biol*. 1996;41(10):2009-26. doi: 10.1088/0031-9155/41/10/011. PubMed PMID: 8912377.

11. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. *J Nucl Med*. 1986;27(9):1490-7. PubMed PMID: 3528417.

12. Spaic R, Ilic R, Dragovic M, Petrovic B. Generation of dose-volume histograms using Monte Carlo simulations on a multicellular model in radionuclide therapy. *Cancer Biother Radiopharm*. 2005;20(3):320-4. doi: 10.1089/cbr.2005.20.320. PubMed PMID: 15989478.

13. O’Donoghue JA, Bardíes M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. *J Nucl Med*. 1995;36(10):1902-9. PubMed PMID: 7562062.

14. Wong FC. MIRD: radionuclide data and decay schemes. *JNM*. 2009;50(12):2091. doi: 10.2967/jnumed.109.069948.

15. Khan FM, Gibbons JP. Khan’s the physics of radiation therapy. Lippincott Williams & Wilkins; 2014.
16. De Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. *J Nucl Med*. 2005;46(Suppl 1):13S-7S. PubMed PMID: 15653647.

17. Navalkissoor S, Flux G, Bomanji J. Molecular radiotheranostics for neuroendocrine tumours. *Clin Med (Lond)*. 2017;17(5):462-8. doi: 10.7861/clinmedicine.17-5-462. PubMed PMID: 28974600. PubMed PMCID: PMC6301943.